Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1

Most muscle pathologies are characterized by the progressive loss of muscle tissue due to chronic degeneration combined with the inability of regeneration machinery to replace the damaged muscle. These pathological changes, known as muscle wasting, can be attributed to the activation of several proteolytic systems, such as calpain, ubiquitin-proteasome and caspases, and to the alteration in muscle growth factors. Among them, insulin-like growth factor-1 (IGF-1) has been implicated in the control of skeletal muscle growth, differentiation, survival, and regeneration and has been considered a promising therapeutic agent in staving off the advance of muscle weakness. Here we review the molecular basis of muscle wasting associated with diseases, such as sarcopenia, muscular dystrophy and Amyotrophic Lateral Sclerosis, and discuss the potential therapeutic role of local IGF-1 isoforms in muscle aging and diseases.

[1]  E. Dargelos,et al.  Calcium-dependent proteolytic system and muscle dysfunctions: a possible role of calpains in sarcopenia. , 2008, Biochimie.

[2]  A. Musarò,et al.  Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model , 2005, The Journal of cell biology.

[3]  A. Musarò,et al.  Local expression of mIgf-1 modulates ubiquitin, caspase and CDK5 expression in skeletal muscle of an ALS mouse model , 2008, Neurological research.

[4]  P. Anversa,et al.  Overexpression of insulin-like growth factor-1 attenuates the myocyte renin-angiotensin system in transgenic mice. , 1999, Circulation research.

[5]  A. M. Rosenthal.  The Critical Role of Insulin-Like Growth Factor-1 Isoforms in the Physiopathology of Skeletal Muscle , 2006 .

[6]  Inna N Lavrik,et al.  Caspases: pharmacological manipulation of cell death. , 2005, The Journal of clinical investigation.

[7]  J. D. Porter,et al.  A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. , 2002, Human molecular genetics.

[8]  M. Rudnicki,et al.  Cellular and molecular regulation of muscle regeneration. , 2004, Physiological reviews.

[9]  B. Russell,et al.  Expression of insulin growth factor‐1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation , 1999, The Journal of physiology.

[10]  R. Schwartz,et al.  Local insulin‐like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  K. Campbell,et al.  Molecular basis of muscular dystrophies , 2000, Muscle & nerve.

[12]  C. Howe,et al.  SUBCUTANEOUS IGF-1 IS NOT BENEFICIAL IN 2-YEAR ALS TRIAL , 2009, Neurology.

[13]  K. Campbell,et al.  Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. , 2002, Current opinion in genetics & development.

[14]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[15]  James M. Allen,et al.  Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  N. Rosenthal,et al.  Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. , 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[17]  F. Gage,et al.  Retrograde Viral Delivery of IGF-1 Prolongs Survival in a Mouse ALS Model , 2003, Science.

[18]  Antonio Musarò,et al.  Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle , 2001, Nature Genetics.

[19]  T. Toda,et al.  The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis , 2006, Journal of Human Genetics.

[20]  C. Roberts,et al.  Insulin-like growth factor I (IGF-I): A molecular basis for endocrine versus local action? , 1991, Molecular and Cellular Endocrinology.

[21]  C. Roberts,et al.  Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro. , 1990, Molecular endocrinology.

[22]  A. Musarò,et al.  Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. , 2008, Cell metabolism.

[23]  A. Musarò,et al.  Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice , 2002, The Journal of cell biology.

[24]  S. Fulle,et al.  Age‐Dependent Effects on Functional Aspects in Human Satellite Cells , 2007, Annals of the New York Academy of Sciences.

[25]  D. Cleveland,et al.  ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.

[26]  A. Musarò,et al.  Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Musarò,et al.  Insulin-like growth factor isoforms in skeletal muscle aging, regeneration, and disease. , 2002, Cold Spring Harbor symposia on quantitative biology.

[28]  P. Caroni,et al.  Accumulation of SOD1 Mutants in Postnatal Motoneurons Does Not Cause Motoneuron Pathology or Motoneuron Disease , 2002, The Journal of Neuroscience.